Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
26.8M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
13.1M
-
Shares change
-
+3.17M
-
Total reported value, excl. options
-
$175M
-
Value change
-
+$42.3M
-
Put/Call ratio
-
0.01
-
Number of buys
-
51
-
Number of sells
-
-14
-
Price
-
$13.32
Significant Holders of Eton Pharmaceuticals, Inc. - Common Stock (ETON) as of Q4 2024
77 filings reported holding ETON - Eton Pharmaceuticals, Inc. - Common Stock as of Q4 2024.
Eton Pharmaceuticals, Inc. - Common Stock (ETON) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.1M shares
of 26.8M outstanding shares and own 48.92% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.85M shares), EcoR1 Capital, LLC (1.83M shares), Nantahala Capital Management, LLC (1.12M shares), VANGUARD GROUP INC (1.06M shares), Westside Investment Management, Inc. (575K shares), Mink Brook Asset Management LLC (456K shares), CANNELL CAPITAL LLC (381K shares), BlackRock, Inc. (318K shares), Parkman Healthcare Partners LLC (277K shares), and GEODE CAPITAL MANAGEMENT, LLC (269K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.